HLK 1008
Alternative Names: HLK-1008Latest Information Update: 30 Jun 2022
At a glance
- Originator HLK Pharmacin
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Jun 2022 HLK Pharmacin has patent protection for preparation platform technology (HLK Pharmacin pipeline, June 2022)
- 22 Jun 2022 HLK 1008 is available for licensing as of 22 Jun 2022. https://pharmacin.com/#about-us
- 22 Jun 2022 Preclinical trials in Cancer in USA (unspecified route) prior to June 2022 (HLK Pharmacin pipeline, June 2022)